Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Translational Neurodegeneration
Published in: Translational Neurodegeneration 1/2016

Open Access 01-12-2016 | Research

Salidroside reduces tau hyperphosphorylation via up-regulating GSK-3β phosphorylation in a tau transgenic Drosophila model of Alzheimer’s disease

Authors: Bei Zhang, Qiongqiong Li, Xingkun Chu, Suya Sun, Shengdi Chen

Published in: Translational Neurodegeneration | Issue 1/2016

Login to get access

Abstract

Background

Alzheimer’s disease (AD) is an age-related and progressive neurodegenerative disease that causes substantial public health care burdens. Intensive efforts have been made to find effective and safe treatment against AD. Salidroside (Sal) is the main effective component of Rhodiola rosea L., which has several pharmacological activities.
The objective of this study was to investigate the efficacy of Sal in the treatment of AD transgenic Drosophila and the associated mechanisms.

Methods

We used tau transgenic Drosophila line (TAU) in which tau protein is expressed in the central nervous system and eyes by the Gal4/UAS system. After feeding flies with Sal, the lifespan and locomotor activity were recorded. We further examined the appearance of vacuoles in the mushroom body using immunohistochemistry, and detected the levels of total glycogen synthase kinase 3β (t-GSK-3β), phosphorylated GSK-3β (p-GSK-3β), t-tau and p-tau in the brain by western blot analysis.

Results

Our results showed that the longevity was improved in salidroside-fed Drosophila groups as well as the locomotor activity. We also observed less vacuoles in the mushroom body, upregulated level of p-GSK-3β and downregulated p-tau following Sal treatment.

Conclusion

Our data presented the evidence that Sal was capable of reducing the neurodegeneration in tau transgenic Drosophila and inhibiting neuronal loss. The neuroprotective effects of Sal were associated with its up-regulation of the p-GSK-3β and down-regulation of the p-tau.
Literature
1.
Wimo A, et al. The worldwide economic impact of dementia 2010. Alzheimers Dement. 2013;9(1):1–11. e3.CrossRefPubMed
2.
3.
Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353–6.CrossRefPubMed
4.
5.
Scholz T, Mandelkow E. Transport and diffusion of Tau protein in neurons. Cell Mol Life Sci. 2014;71(16):3139–50.CrossRefPubMed
6.
Ballatore C, et al. Microtubule stabilizing agents as potential treatment for Alzheimer’s disease and related neurodegenerative tauopathies. J Med Chem. 2012;55(21):8979–96.CrossRefPubMedPubMedCentral
7.
Brunden KR, et al. Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochem Soc Trans. 2012;40(4):661–6.CrossRefPubMedPubMedCentral
8.
9.
Grundke-Iqbal I, et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83(13):4913–7.CrossRefPubMedPubMedCentral
10.
Grundke-Iqbal I, et al. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem. 1986;261(13):6084–9.PubMed
11.
Iqbal K, et al. Defective brain microtubule assembly in Alzheimer’s disease. Lancet. 1986;2(8504):421–6.CrossRefPubMed
12.
Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A. 1986;83(11):4044–8.CrossRefPubMedPubMedCentral
13.
Gomez-Isla T, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease. Ann Neurol. 1997;41(1):17–24.CrossRefPubMed
14.
15.
Obulesu M, Venu R, Somashekhar R. Tau mediated neurodegeneration: an insight into Alzheimer’s disease pathology. Neurochem Res. 2011;36(8):1329–35.CrossRefPubMed
16.
17.
Zhu Y, et al. Salidroside protects against hydrogen peroxide-induced injury in cardiac H9c2 cells via PI3K-Akt dependent pathway. DNA Cell Biol. 2011;30(10):809–19.CrossRefPubMed
18.
Shi K, et al. Salidroside protects retinal endothelial cells against hydrogen peroxide-induced injury via modulating oxidative status and apoptosis. Biosci Biotechnol Biochem. 2015;79(9):1406–13.CrossRefPubMed
19.
Jin H, et al. Therapeutic intervention of learning and memory decays by salidroside stimulation of neurogenesis in aging. Mol Neurobiol. 2016;53(2):851–66.
20.
Feng Y, et al. Optimization on Preparation Conditions of Salidroside Liposome and Its Immunological Activity on PCV-2 in Mice. Evid Based Complement Alternat Med. 2015;2015:178128.PubMedPubMedCentral
21.
Liu S, et al. Salidroside rescued mice from experimental sepsis through anti-inflammatory and anti-apoptosis effects. J Surg Res. 2015;195(1):277–83.CrossRefPubMed
22.
Zhao G, et al. Salidroside inhibits the growth of human breast cancer in vitro and in vivo. Oncol Rep. 2015;33(5):2553–60.PubMed
23.
Li X, et al. Effect of Tongxinluo on nerve regeneration in mice with diabetic peripheral neuropathy. Cell Mol Biol (Noisy-le-Grand). 2015;61(5):103–7.
24.
Xian H, et al. MADP, a salidroside analog, protects hippocampal neurons from glutamate induced apoptosis. Life Sci. 2014;103(1):34–40.CrossRefPubMed
25.
Zhang B, et al. Neuroprotective effects of salidroside through PI3K/Akt pathway activation in Alzheimer’s disease models. Drug Des Devel Ther. 2016;10:1335–43.PubMedPubMedCentral
26.
Xiao L, et al. Salidroside protects Caenorhabditis elegans neurons from polyglutamine-mediated toxicity by reducing oxidative stress. Molecules. 2014;19(6):7757–69.CrossRefPubMed
27.
Wang Y, et al. The combination of aricept with a traditional Chinese medicine formula, smart soup, may be a novel way to treat Alzheimer’s disease. J Alzheimers Dis. 2015;45(4):1185–95.PubMed
28.
Lee FK, et al. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson’s disease. J Neurochem. 2009;110(1):208–19.CrossRefPubMed
29.
Mudher A, et al. GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry. 2004;9(5):522–30.CrossRefPubMed
30.
Folwell J, et al. Abeta exacerbates the neuronal dysfunction caused by human tau expression in a Drosophila model of Alzheimer’s disease. Exp Neurol. 2010;223(2):401–9.CrossRefPubMed
31.
Greeve I, et al. Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J Neurosci. 2004;24(16):3899–906.CrossRefPubMed
32.
33.
Mohamed NV, et al. Spreading of tau pathology in Alzheimer’s disease by cell-to-cell transmission. Eur J Neurosci. 2013;37(12):1939–48.CrossRefPubMed
34.
Iqbal K, Gong CX, Liu F. Microtubule-associated protein tau as a therapeutic target in Alzheimer’s disease. Expert Opin Ther Targets. 2014;18(3):307–18.CrossRefPubMed
35.
Tan Y, Ji YB, Zhao J. Research progress of transgenic Drosophila model of Alzheimer disease. Yao Xue Xue Bao. 2013;48(3):333–6.PubMed
36.
37.
Iijima K, Gatt A, Iijima-Ando K. Tau Ser262 phosphorylation is critical for Abeta42-induced tau toxicity in a transgenic Drosophila model of Alzheimer’s disease. Hum Mol Genet. 2010;19(15):2947–57.CrossRefPubMedPubMedCentral
38.
Gao J, et al. Salidroside ameliorates cognitive impairment in a d-galactose-induced rat model of Alzheimer’s disease. Behav Brain Res. 2015;293:27–33.CrossRefPubMed
39.
40.
Harrington CR, et al. Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease. J Biol Chem. 2015;290(17):10862–75.CrossRefPubMedPubMedCentral
41.
Ma T. GSK3 in Alzheimer’s disease: mind the isoforms. J Alzheimers Dis. 2014;39(4):707–10.PubMed
Metadata
Title
Salidroside reduces tau hyperphosphorylation via up-regulating GSK-3β phosphorylation in a tau transgenic Drosophila model of Alzheimer’s disease
Authors
Bei Zhang
Qiongqiong Li
Xingkun Chu
Suya Sun
Shengdi Chen
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Translational Neurodegeneration / Issue 1/2016
Electronic ISSN: 2047-9158
DOI
https://doi.org/10.1186/s40035-016-0068-y

Other articles of this Issue 1/2016

Translational Neurodegeneration 1/2016 Go to the issue

Research

Clinical characteristics of fatigued Parkinson’s patients and the response to dopaminergic treatment

Research

Beclin-1- mediated autophagy may be involved in the elderly cognitive and affective disorders in streptozotocin-induced diabetic mice

Review

The study of brain functional connectivity in Parkinson’s disease

Research

Methylation status of DJ-1 in leukocyte DNA of Parkinson’s disease patients

Research

The predictive value of SS-16 in clinically diagnosed Parkinson’s disease patients: comparison with 99mTc-TRODAT-1 SPECT scans

Review

Stepping closer to treating Alzheimer’s disease patients with BACE1 inhibitor drugs